Menu
Search
|

Menu

Close
X

FibroGen Inc FGEN.OQ (NASDAQ Stock Exchange Global Select Market)

46.73 USD
+0.53 (+1.15%)
As of 1:09 PM EDT
Previous Close 46.20
Open 46.30
Volume 50,600
3m Avg Volume 259,568
Today’s High 46.79
Today’s Low 45.68
52 Week High 67.65
52 Week Low 33.51
Shares Outstanding (mil) 78.97
Market Capitalization (mil) 4,359.11
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.88 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY19
24
FY18
213
FY17
131
FY16
180
EPS (USD)
FY19
-0.530
FY18
-1.037
FY17
-1.000
FY16
-1.016
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
36.97
7.92
Price to Book (MRQ)
vs sector
17.03
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
49.43
14.56
LT Debt to Equity (MRQ)
vs sector
49.43
10.21
Return on Investment (TTM)
vs sector
-28.39
14.49
Return on Equity (TTM)
vs sector
-58.84
15.79

EXECUTIVE LEADERSHIP

Thomas Neff
Chairman of the Board, Chief Executive Officer, Since 1993
Salary: $840,000.00
Bonus: $693,000.00
Pat Cotroneo
Chief Financial Officer, Since 2008
Salary: $453,000.00
Bonus: $249,150.00
K. Peony Yu
Chief Medical Officer, Since 2016
Salary: $525,000.00
Bonus: $393,750.00
Thomas Kearns
Lead Independent Director, Since 2017
Salary: --
Bonus: --
Suzanne Blaug
Independent Director, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

409 Illinois St
SAN FRANCISCO   CA   94158-2509

Phone: +1415.9781200

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.

SPONSORED STORIES